NVHR Welcomes New Hepatitis B Vaccine

 
 
Share this
 
 

 

NVHR today welcomed the U.S. Food and Drug
Administration’s (FDA) approval of HEPLISAV-B for prevention of hepatitis B
virus infection in adults ages 18 and older. HEPLISAV-B is the first new
hepatitis B vaccine approved in the United States in more than 25 years and the
only two-dose hepatitis B vaccine for adults.